Candel Therapeutics to present extended Phase 3 data on aglatimagene besadenovec in localized prostate cancer at ASTRO 2026
CADL•ASTRO 2026 presentation planned for Phase 3 prostate cancer data
Candel Therapeutics set an ASTRO 2026 poster to present extended Phase 3 data for aglatimagene besadenovec in localized prostate cancer.
Results were previously published in The Lancet Oncology; the new presentation is scheduled for September 29, 2026.
The company plans to highlight evidence of immune activation following treatment, supporting its multimodal immunotherapy approach without disclosing new efficacy metrics.
Aglatimagene holds FDA Fast Track and Regenerative Medicine Advanced Therapy designations for newly diagnosed intermediate- to high-risk localized prostate cancer.
